JPH0531107B2 - - Google Patents
Info
- Publication number
- JPH0531107B2 JPH0531107B2 JP59013928A JP1392884A JPH0531107B2 JP H0531107 B2 JPH0531107 B2 JP H0531107B2 JP 59013928 A JP59013928 A JP 59013928A JP 1392884 A JP1392884 A JP 1392884A JP H0531107 B2 JPH0531107 B2 JP H0531107B2
- Authority
- JP
- Japan
- Prior art keywords
- blood cells
- blood
- symptoms
- image
- blood cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000601 blood cell Anatomy 0.000 claims description 67
- 208000024891 symptom Diseases 0.000 claims description 50
- 239000004615 ingredient Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 238000004159 blood analysis Methods 0.000 claims description 7
- 230000004075 alteration Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 21
- 210000003743 erythrocyte Anatomy 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 108010019160 Pancreatin Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 235000011649 selenium Nutrition 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960000443 hydrochloric acid Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- -1 EpA Chemical compound 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 206010002536 Anisocytosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000018721 Macroglobulins Human genes 0.000 description 1
- 108010091934 Macroglobulins Proteins 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035774 Poikilocytosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000002506 abnormal erythrocyte Anatomy 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 210000002652 macrocyte Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Image Processing (AREA)
- Image Analysis (AREA)
Description
【発明の詳細な説明】
本発明は採取した血液細胞が変質していない血
液中の血液細胞の状態を調べてその症状に応じた
有効投与成分等を自動的に指示する血液の自動分
析判定指示方法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention provides an automatic blood analysis and judgment instruction that examines the condition of blood cells in the blood in which the collected blood cells are not altered and automatically instructs effective administration ingredients according to the symptoms. Regarding the method.
近年、食品、食品添加物、嗜好品等の多様化に
伴つて栄養のバランスを崩し易くしたり、各種薬
品、化粧品等の多様化に伴つて各種のアレルギー
体質を呈する人が増加して来た。 In recent years, the diversification of foods, food additives, luxury goods, etc. has made it easier to lose nutritional balance, and the diversification of various drugs, cosmetics, etc. has led to an increase in the number of people suffering from various allergies. .
しかしながら、同様な症状を呈していても個体
差があるので同じ薬、ビタミン、ミネラル等を投
与しても治療効果に差が生じてしまう。 However, even if patients exhibit similar symptoms, there are individual differences, so even if the same drugs, vitamins, minerals, etc. are administered, there will be differences in the therapeutic effects.
従つて、各個体に適正な有効成分等を選択して
投与することが必要である。 Therefore, it is necessary to select and administer appropriate active ingredients to each individual.
この個体差に応じた症状を正確に把握するに
は、病気等の症状を呈する人の血液細胞を調査し
て判定する方法がある。 In order to accurately understand the symptoms depending on individual differences, there is a method of examining and determining the blood cells of a person exhibiting symptoms of a disease or the like.
このような判定を、顕微鏡によつて血液細胞を
拡大視してコンピユータ等を用いて症状を示すデ
ータと比較することにより、自動的に行なう方法
が、例えば、特開昭56−133659号公報、特開昭57
−103059号公報、特開昭57−153367号公報、特開
昭58−223868号公報および特開昭54−119294号公
報等に示されている。 For example, Japanese Patent Laid-Open No. 133659/1983 discloses a method of automatically performing such a determination by magnifying blood cells using a microscope and comparing the data with data showing symptoms using a computer or the like. Unexamined Japanese Patent Publication 1987
This method is disclosed in Japanese Patent Application Laid-open No. 103059, Japanese Patent Application Laid-Open No. 153367-1982, Japanese Patent Application Laid-Open No. 223868-1982, and Japanese Patent Application Laid-open No. 119294-1984.
これらの各公報に記載されている従来方法にお
いては、顕微鏡による観察の前に、顕微鏡標本を
作成していた。すなわち、病気等の症状を呈する
人から注射器を用いて約10cc程度採取した各種の
血液検査用の血液より、所定量の血液を取出して
スライドグラス上に落し、その後に染色したり、
凝固させて顕微鏡標本を作成し、その標本につい
て血液検査するようにしていた。 In the conventional methods described in each of these publications, a microscopic specimen was prepared before observation using a microscope. In other words, approximately 10 cc of blood for various blood tests is collected using a syringe from a person exhibiting symptoms of a disease, etc., and a predetermined amount of blood is taken out and dropped onto a slide glass, and then stained.
They would coagulate it and make a microscopic specimen, which would then be subjected to blood tests.
ところが、染色され、凝固している血液細胞
は、人体内を流れている生の血液細胞が変質した
ものであるために、生の血液細胞が呈する症状に
対応した状態を全く同様に示すことができない。
従つて、前記従来方法によつては、生の血液細胞
中に包含されている症状に対応した貴重なデータ
をみすみすのがして症状の判定を行なつているも
のであり、症状を適格に判定することが不可能で
あつた。 However, since stained and coagulated blood cells are altered versions of living blood cells flowing through the human body, they cannot exhibit the same symptoms as those of living blood cells. Can not.
Therefore, the conventional method described above bypasses valuable data corresponding to the symptoms contained in living blood cells to judge the symptoms. It was impossible to judge.
また、前記従来方法においては、顕微鏡標本作
成に長時間を要するものであり、緊急な判定に用
いることができなかつた。 In addition, the conventional method requires a long time to prepare a microscopic specimen, and cannot be used for emergency diagnosis.
更に、今日においては健康管理を重視する傾向
にあり、特に女性においては化粧のための肌の健
康具合を常時管理することを心がけている人が増
加している。このような現状により、健康度の判
定を、簡単な方法により、適格に行なうことがで
きる方法の出現が要請されている。 Furthermore, nowadays there is a tendency to place importance on health management, and an increasing number of people, especially women, are constantly trying to maintain the health of their skin in order to apply makeup. Under these circumstances, there is a demand for a method that can accurately determine the level of health using a simple method.
本発明はこのような医療や健康についての背景
の下においてなされたものである。 The present invention was made against this medical and health background.
本発明の血液の自動分析判定指示方法は発明者
等の医療関係者の、永年の臨床医学的なデータの
集積、分析等により確立されたものである。 The automatic blood analysis/determination instruction method of the present invention was established through many years of clinical medical data collection and analysis by medical personnel such as the inventor.
以下、その臨床医学的事実を、変質していない
生の血液細胞の顕微鏡写真である第1図から第2
1図について説明する。この顕微鏡写真の倍率は
1000倍である。 The clinical medical facts are explained below in Figures 1 to 2, which are micrographs of unaltered raw blood cells.
Figure 1 will be explained. The magnification of this micrograph is
It is 1000 times more.
(1) 症状;
赤血球の連鎖状態(Rouleau)…第1図
血液細胞像;
赤血球がコインを積み重ねた様に集合してい
る。(1) Symptoms: Chaining of red blood cells (Rouleau)...Figure 1 Blood cell image: Red blood cells are clustered together like a stack of coins.
内 容;
線維細胞への酸素供給の減少により、人体に疲
労を生じる。Contents: A decrease in oxygen supply to fiber cells causes fatigue in the human body.
有効投与成分;
塩酸(HCl)、ナイアシン(ビタミンB3)
(2) 症状;
赤血球集合体(Erythrocyte Aggregation)…
第2図
血液細胞像;
赤血球が規則性なく多数集合している。Active ingredients: Hydrochloric acid (HCl), niacin (vitamin B3 ) (2) Symptoms: Erythrocyte Aggregation...
Figure 2 Image of blood cells; Red blood cells are gathered in large numbers without regularity.
内 容; 肥満の原因となり、赤血球沈降異常を呈する。Content; It causes obesity and exhibits abnormal erythrocyte sedimentation.
有効投与成分;
塩酸、ナイアシン、ヘパリン(肝臓中に多く存
する血液の凝固を防ぐ物質)
(3) 症状;
紡錘細胞凝集集合体(Thrombocyte
Aggregation)…第3図
血液細胞像;
血小板が凝集している。Active ingredients: Hydrochloric acid, niacin, heparin (substances that prevent blood clotting, which are present in large quantities in the liver) (3) Symptoms: Spindle cell aggregates (Thrombocyte
Aggregation)...Figure 3 Blood cell image; Platelets are aggregated.
内 容;
循環障害、脈博障害、凝血、頭痛等を起し易く
なる。Contents: Increases the likelihood of circulatory disorders, pulse disorders, blood clots, headaches, etc.
有効投与成分;
EPA、ビタミンC、E、B6、マグネシウム、
マンガン、パンクレアチン(消化酵素)
(4) 症状;
針骨(Spicules)…第4図
血液細胞像;
小さな針状の物質が析出している。これらの物
質は、フイブリン(血液凝固の際に形成される繊
維状蛋白質)またはマクログロブリンと考えられ
る。この針骨は赤血球集合体と一緒に発生するこ
とが多い。Active ingredients: EPA, vitamin C, E, B6 , magnesium,
Manganese, pancreatin (digestive enzyme) (4) Symptoms: Spicules...Figure 4 Image of blood cells: Small needle-like substances are precipitated. These substances are thought to be fibrin (fibrous proteins formed during blood clotting) or macroglobulins. These spicules often occur together with red blood cell aggregates.
内 容; 肝機能の低下、ストレス、疲れを感じる。Content; Feeling of decreased liver function, stress, and fatigue.
有効投与成分;
塩酸、ナイアシン、鉄、玄米胚芽、イノシトー
ル、メチオニン
(5) 症状;
乳糜状物質(Chylous Material)…第5図
血液細胞像;
かゆ状の物質が血液中に析出している。Active ingredients: Hydrochloric acid, niacin, iron, brown rice germ, inositol, methionine (5) Symptoms: Chylous material...Figure 5 Image of blood cells: An itchy substance is precipitated in the blood.
内 容;
高脂肪血液、肝機能低下特に脂肪の消化ができ
ない状態が発生している。Details: High-fat blood, decreased liver function, and in particular, an inability to digest fat.
有効投与成分;
コリン、イノシトール、メチオニン、低飽和脂
肪食のようなレシチン(大豆、卵黄を原料とする
肝臓薬)、リポトロフイツク(肝臓脂肪の沈着を
防止するもの)、野菜、イオン
(6) 症状;
エル形態(L−Forms)…第6図
血液細胞像;
光つて少し大きい。よく動き回わる。前記乳糜
状物質の大きいものと混同してはならない。Active ingredients: choline, inositol, methionine, lecithin (liver medicine made from soybeans and egg yolks), lipotrophic (prevents liver fat deposition), vegetables, ions (6) such as low saturated fat diet Symptoms; L-Forms...Figure 6 Image of blood cells; Shiny and slightly large. Moves around a lot. It should not be confused with the larger version of the chyle-like substance.
内 容;
血液中のバクテリヤが多くなり、低免疫性とな
り、病気の抵抗力低下となる。Contents: The number of bacteria in the blood increases, resulting in low immunity and reduced resistance to diseases.
有効投与成分;
ビタミンA、B、C、E、セレン、亜鉛、ラク
トバチルス菌、アシドフイルス菌、ヨーグルト、
ミネラル
(7) 症状;
ロツド形態(Rod Forms)…第7図
血液細胞像;
ロツド状のものが析出する。Active ingredients: vitamins A, B, C, E, selenium, zinc, lactobacillus, acidophilus, yogurt,
Minerals (7) Symptoms; Rod Forms...Figure 7 Image of blood cells; Rod-shaped substances precipitate.
内 容;
子供はめまいが多くなる。がんの免疫性がなく
なり、がんの発生率が高い。Contents: Children often experience dizziness. Cancer immunity is lost and the incidence of cancer is high.
有効投与成分; エル形態の場合と同様である。Active administration ingredient; The same is true for the L form.
(8) 症状;
寄生RBC(Parasitized RBC)…第8図
血液細胞像;
赤血球がバクテリアに冒された感染赤血球とし
て観察される。(8) Symptoms; Parasitized RBC...Figure 8 Image of blood cells; Red blood cells are observed as infected red blood cells affected by bacteria.
内 容;
疲労過多になり易く、風邪をひき易く、化膿し
易く、アレルギーを起し易い。Contents: Easily fatigued, easily catch colds, susceptible to suppuration, and prone to allergies.
有効投与成分;
エル形態の有効投与成分、並びにパントテン
酸、ガーリツク・抗生物質、抗アレルギー剤、β
−カロチン
(9) 症状;
原形物質(Protoplast)…第9図
血液細胞像;
赤血球より大きいバクテリア状に見える。毒素
を多く含むと赤色に光る。白色はただのバクテリ
アである。Effective administration ingredients: Effective administration ingredients in L form, as well as pantothenic acid, garlic antibiotics, antiallergic agents, β
-Carotene (9) Symptoms: Protoplast...Figure 9 Image of blood cells; Looks like bacteria, larger than red blood cells. It glows red when it contains a lot of toxins. The white color is just bacteria.
内 容; がん、結核等の呼吸器病、梅毒。Content; Cancer, respiratory diseases such as tuberculosis, and syphilis.
有効投与成分;
ビタミンC、E、天然総合ミネラル、セレン、
カロチン、パンクレアチン、抗炎症酵素。Active ingredients: vitamins C, E, natural minerals, selenium,
Carotene, pancreatin, anti-inflammatory enzymes.
(10) 症状;
溶菌斑(Plaque)…第10図
血液細胞像;
原形物質より透明感がなくバクテリア状に見え
る。赤い結晶体を持つことがある。(10) Symptoms: Plaques...Figure 10 Image of blood cells; They are less transparent than the original substance and look like bacteria. May have red crystals.
内 容;
心臓病、動脈硬化、血液循環機能低下、血行障
害、新陳代謝低下、各種アレルギー、あざができ
やすい。Contents: Heart disease, arteriosclerosis, decreased blood circulation, blood circulation disorders, decreased metabolism, various allergies, and easy bruising.
有効投与成分;
マグネシウム、ビタミンB6、カリウム、ビタ
ミンB15、C、E、鉄分、パンクレアチン、
EpA、スクアラン、アスパラギン酸、ガーリツ
ク、ナイアシン
(11) 症状;
赤い結晶体(Red Crystals)…第11図
血液細胞像;
第11図ではモノクロで実際の色は見えない
が、カラーで見ると赤色の結晶体状をしている。Active ingredients: Magnesium, vitamin B 6 , potassium, vitamin B 15 , C, E, iron, pancreatin,
EpA, squalane, aspartic acid, garlic, niacin (11) Symptoms: Red crystals...Figure 11 Blood cell image; Figure 11 is monochrome and the actual color cannot be seen, but when viewed in color, it appears red. It has a crystalline shape.
内 容;
動脈硬化、高血圧、心不全、毒素が多い、ガン
有効投与成分;
エンチーム(酵素)、漢方薬、米の葉、乳酸菌、
消化酵素、アシドフイルス菌、ヨーグルト、毒素
洗滌剤
(12) 症状;
表皮肥厚症(Acanthrocyte Percentage)…第
12図
血液細胞像;
変形の激しい赤血球が見られる。ただし、1視
野中1%以下の場合は有意ではない。Contents: Arteriosclerosis, high blood pressure, heart failure, high levels of toxins, effective cancer ingredients: Enzyme, Chinese herbal medicine, rice leaves, lactic acid bacteria,
Digestive enzymes, acidophilus bacteria, yogurt, toxin detergent (12) Symptoms: Acanthrocyte Percentage...Figure 12 Blood cell image: Severely deformed red blood cells are seen. However, if it is 1% or less in one field of view, it is not significant.
内 容; 血液浄化作用低下、アレルギーが起り易い。Content; Blood purification effect decreases and allergies are likely to occur.
有効投与成分;
塩酸、ナイアシン、ビタミンC、E、漢方薬、
抗アレルギー剤
(13) 症状;
好中球増加生育力(Neutrophilic Viability)
…第13図
血液細胞像;
赤血球の凝集により好中球の活動が不活発とな
る。Active ingredients: hydrochloric acid, niacin, vitamins C, E, Chinese herbal medicine,
Anti-allergic agents (13) Symptoms; Neutrophilic Viability
...Figure 13 Image of blood cells; Due to agglutination of red blood cells, neutrophil activity becomes inactive.
内 容;
白血球の活性度低下
有効投与成分;
塩酸、抗酸化剤(ビタミンE)、ビタミンB15、
セレン
(14) 症状;
好中球細胞分裂過敏症(Hypersegmentation
of Neutrophils)…第14図
血液細胞像;
白血球細胞の分裂が過多となつて見える。Contents: Effective ingredients for reducing leukocyte activity: Hydrochloric acid, antioxidant (vitamin E), vitamin B15 ,
Selenium (14) Symptoms; Hypersegmentation of neutrophils
of Neutrophils)...Figure 14 Image of blood cells; White blood cells appear to be dividing excessively.
内 容;
葉酸不足、耐バクテリア性の弱化
有効投与成分;
ビタミンB(イースト菌、レバー、胚芽)、玄米
胚芽、ビタミンE、B12
(15) 症状;
好酸球増多症(Eosinophils)…第15図
血液細胞像;
分裂した白血球が前記好中球細胞分裂過多症の
場合より大きく、光つてみえる。Contents: Folic acid deficiency, weakened bacterial resistance Active ingredients: Vitamin B (yeast, liver, germ), brown rice germ, vitamin E, B12 (15) Symptoms: Eosinophils...No. 15 Image of blood cells: Divided white blood cells appear larger and brighter than in the case of neutrophil hypermitosis.
内 容;
アレルギー症状、寄性体質、腫瘍
有効投与成分;
ビタミンA、C、E、B6、パンクレアチン、
カルシウム、抗アレルギー剤
(16) 症状;
標的赤血球(Target Cells)…第16図
血液細胞像;
赤血球の中央部が白色になつて見える。Contents: Allergy symptoms, parasitic constitution, tumor active ingredients: Vitamins A, C, E, B6 , pancreatin,
Calcium, anti-allergic agent (16) Symptoms: Target Cells...Figure 16 Image of blood cells: The center of the red blood cells appears white.
内 容;
慢性貧血症、冷え症、鉄欠乏性貧血症、甲状腺
ホルモン低下症
有効投与成分;
鉄、ビタミンB群
(17) 症状;
アニス酸細胞(Anisocytosis)…第17図
血液細胞像;
赤血球の大きさが不揃い
内 容;
激しい貧血、巨赤芽球貧血
有効投与成分;
鉄、ビタミンB12、A、E、葉酸、漢方薬、ジ
ンセン
(18) 症状;
変形赤血球症(Poikilocytosis)…第18図
血液細胞像;
変形した赤血球が見られる。Contents: Chronic anemia, sensitivity to cold, iron deficiency anemia, hypothyroid hormone Active ingredients: Iron, vitamin B group (17) Symptoms: Anisocytosis...Figure 17 Blood cell image: Size of red blood cells Contents: Severe anemia, megaloblastic anemia Active ingredients: Iron, vitamin B12 , A, E, folic acid, Chinese herbal medicine, ginseng (18) Symptoms: Poikilocytosis...Figure 18 Blood cells Image: Deformed red blood cells are seen.
内 容;
貧血、めまい、不定愁訴
有効投与成分;
ビタミンE、B12、A、C、葉酸、β−カロチ
ン、セレン、鉄、抗酸化剤体
(19) 症状;
卵形細胞(Ovalocytes)…第19図
血液細胞像;
赤血球が卵形に変形している。Contents: Anemia, dizziness, indefinite complaints Active ingredients: Vitamin E, B12 , A, C, folic acid, β-carotene, selenium, iron, antioxidants (19) Symptoms: Oval cells...No. Figure 19 Image of blood cells; Red blood cells are deformed into an oval shape.
内 容;
貧血、めまい
有効投与成分;
鉄、葉酸、ビタミンB12
(20) 症状;
大赤血球(Macrocytes)…第20図
血液細胞像;
直径が9ミクロンより大きい赤血球が見られ
る。Contents: Anemia, dizziness Active ingredients: Iron, folic acid, vitamin B 12 (20) Symptoms: Macrocytes...Figure 20 Blood cell image: Red blood cells larger than 9 microns in diameter are seen.
内 容;
溶血性貧血
有効投与成分;
ビタミンB12、葉酸
(21) 症状;
小赤血球(Microcytes)…第21図
血液細胞像;
直径が6ミクロンより小さい赤血球が見られ
る。Contents: Active ingredients for hemolytic anemia: Vitamin B12 , folic acid (21) Symptoms: Microcytes...Figure 21 Blood cell image: Red blood cells smaller than 6 microns in diameter are seen.
内 容;
貧血
有効投与成分
ビタミンB12、鉄、葉酸
本発明は前述した臨床医学的事実に基づいてな
されたものであり、変質していない生の血液細胞
を分析して症状を調べ、それにより、病気を予知
し且つ予防医学的に健康を保持するために不足し
がちな有効投与成分を表示することのできる血液
の自動分析判定指示方法を提供することを目的と
する。Contents: Effective ingredients for administering anemia Vitamin B12 , iron, folic acid The present invention was made based on the clinical medical facts mentioned above, and involves analyzing raw, unaltered blood cells to examine symptoms. An object of the present invention is to provide an automatic blood analysis determination instruction method that can predict diseases and display effective administration ingredients that tend to be in short supply in order to maintain health from a preventive medicine perspective.
本発明は患者の耳たぶ等から採取した少量の血
液細胞が変質していない生の血液細胞を顕微鏡に
よつて拡大し、その血液細胞像から前記の各血液
細胞状態があることを検知し、その内容を予め記
憶していた各症状と比較し、症状を決定するとと
もにその症状に適正な有効投与成分を指示するよ
うに形成したものである。 The present invention uses a microscope to magnify a small amount of raw, unaltered blood cells collected from a patient's earlobe, etc., and detects each of the above-mentioned blood cell states from the image of the blood cells. The content is compared with each symptom stored in advance to determine the symptom and to instruct the appropriate effective ingredient to be administered for that symptom.
以下、本発明方法を実施する装置を示す第22
図について説明する。 Hereinafter, No. 22 showing the apparatus for carrying out the method of the present invention will be described.
The diagram will be explained.
図中、符号1は顕微鏡であり、患者から採血し
た変質していない生の血液細胞を拡大し、血液細
胞の状態の判定を行ない易くする。この顕微鏡1
には主として光学式顕微鏡を用いるが、必要に応
じて電子顕微鏡を用いてもよい。また、生の血液
細胞を顕微鏡1によつて容易に観察できるように
するために、スライドグラス上に所定高さの環状
の堤を設け、その内側に患者の耳たぶ等から採取
した少量の血液を入れて、所定厚さの血液膜を形
成するようにするとよい。この顕微鏡1にはテレ
ビカメラ2が取付けられており、拡大された血液
細胞像を撮像し、その信号2aをテレビ等のデイ
スプレー機3へ送る。そして、このデイスプレー
機3は拡大された血液細胞像を画面3aに映し出
し、目視による医師ならびに患者の利用に供す
る。このデイスプレー機3には、血液細胞像中に
前記各種血液細胞があることを検出し、その血液
細胞状態に応じたデータ信号4aを発するデータ
採取器4が連設されている。このデータ採取器4
は、デイスプレー機3の画面3aに映し出された
血液細胞像をスキヤンして、含まれている血液細
胞の種類とその数を検出するAD変換器5と、そ
の血液細胞の種類とその数とを記憶するとともに
データ信号4aとして出力する記憶器6とにより
形成されている。このデータ信号4aは演算器7
の演算部8へ送られる。この演算部8には記憶器
9が接続されている。この記憶器9内へは、予め
前記各種の変質していない生の血液細胞状態と、
その血液細胞状態に相当する症状と、その症状へ
の有効投与成分とを記憶させてある。そして、演
算部8においてはデータ信号4aを記憶器9の記
憶事項と比較し、現在画面3aに映し出されてい
る血液細胞状態がどの症状に該当するかを決定
し、その後その症状と有効投与成分とを指示する
指示信号7aをデイスプレー機3へ送出する。こ
の指示信号7aを受けたデイスプレー機3は、そ
の症状および有効投与成分を画面3aに映し出
す。この時、画面3aを血液細胞像と症状等とを
切換えてもよく、また、両者を同時に映し出すよ
うにしてもよい。また、演算器7の演算部8に
は、症状および有効投与成分を別に打出すプリン
タ10が接続されている。 In the figure, reference numeral 1 denotes a microscope, which magnifies raw, unaltered blood cells collected from a patient to facilitate determination of the state of the blood cells. This microscope 1
Although an optical microscope is mainly used for this purpose, an electron microscope may be used if necessary. In addition, in order to easily observe live blood cells using the microscope 1, a ring-shaped bank of a predetermined height is provided on the slide glass, and a small amount of blood collected from the patient's earlobe is placed inside the ring-shaped bank. to form a blood film of a predetermined thickness. A television camera 2 is attached to this microscope 1, which takes an enlarged image of blood cells and sends the signal 2a to a display device 3 such as a television. The display device 3 projects an enlarged blood cell image on a screen 3a for visual viewing by doctors and patients. This display device 3 is connected with a data collector 4 that detects the presence of the various blood cells in the blood cell image and generates a data signal 4a corresponding to the state of the blood cells. This data collector 4
The AD converter 5 scans the blood cell image displayed on the screen 3a of the display device 3 and detects the type and number of blood cells contained therein, and the and a memory device 6 which stores the data and outputs it as a data signal 4a. This data signal 4a is
It is sent to the arithmetic unit 8. A memory device 9 is connected to this calculation section 8 . Into this storage device 9, the states of the various unaltered raw blood cells are stored in advance;
Symptoms corresponding to the blood cell condition and effective administration ingredients for the symptoms are stored. Then, the calculation unit 8 compares the data signal 4a with the items stored in the memory device 9, determines which symptom the blood cell state currently displayed on the screen 3a corresponds to, and then compares the symptom with the effective administration ingredient. An instruction signal 7a is sent to the display device 3. The display device 3 that receives this instruction signal 7a displays the symptom and the active ingredient on the screen 3a. At this time, the screen 3a may be switched between a blood cell image and a symptom, or both may be displayed at the same time. Further, a printer 10 is connected to the calculation section 8 of the calculation unit 7, which prints out the symptoms and the effective administration ingredients separately.
次に、発明方法の判定を説明する。 Next, the determination of the invention method will be explained.
先ず、患者から採取した変質していない生の血
液を顕微鏡1で例えば1000倍程度に拡大する。こ
の拡大された血液細胞像はテレビカメラ2により
自動的に撮像され、デイスプレー機3の画面3a
に映し出される。これにより医師ならびに患者
は、患者からの採血後直に数分以内に血液細胞の
状態がどのようになつているかを目視により観察
することができる。 First, unaltered raw blood collected from a patient is magnified, for example, about 1000 times using a microscope 1. This enlarged blood cell image is automatically captured by the television camera 2, and the image is captured on the screen 3a of the display device 3.
will be displayed on the screen. This allows doctors and patients to visually observe the state of blood cells within several minutes immediately after blood is collected from the patient.
そして、この血液細胞像はデータ採取器4の
AD変換器5により自動的にスキヤンされ、その
内に含まれる血液細胞の種類とその数とが検出さ
れる。このようにして検出された血液細胞の種類
とその数とは、記憶器6により記憶されるととも
にデータ信号4aとして演算器7の演算部8へ送
出される。この演算部8はデータ信号4aの内容
を記憶器9へ予め記憶させてある情報と比較し、
現在画面に映し出されている血液細胞像に相当す
る症状と有効投与成分とを決定し、指示信号7a
をデイスプレー機3に向けて発する。その後、デ
イスプレー機3は、指示信号7aに基づく症状と
有効投与成分とを、画面3aに血液細胞像と一緒
にまたは切換えて映し出す。これにより、医師は
正確な症状と有効投与成分とを迅速に決定するこ
とができる。 This blood cell image is then captured by the data collector 4.
The blood cells are automatically scanned by the AD converter 5, and the type and number of blood cells contained therein are detected. The type and number of blood cells detected in this manner are stored in the memory 6 and sent to the calculation section 8 of the calculation unit 7 as a data signal 4a. This calculation unit 8 compares the contents of the data signal 4a with information stored in advance in the storage device 9,
The symptoms and effective administration ingredients corresponding to the blood cell image currently displayed on the screen are determined, and the instruction signal 7a is determined.
is emitted towards display device 3. Thereafter, the display device 3 displays the symptoms and effective administration ingredients based on the instruction signal 7a on the screen 3a together with the blood cell image or in a switched manner. This allows the physician to quickly determine the exact symptoms and active ingredients to administer.
なお、必要に応じてプリンタ10によりその症
状と有効投与成分との文字により打出すとよい。 Note that, if necessary, the symptoms and the active ingredients to be administered may be printed out in letters using the printer 10.
このように本発明の血液の自動分析判定指示方
法は、患者から採取した小量の変質していない生
の血液を顕微鏡により拡大する操作を行なうだけ
で、その血液細胞像を画面で目視することがで
き、医師の診断並びに患者への説明に供すること
ができる。また、その後もその血液細胞像に相当
する症状と有効投与成分とを自動的に検出し、判
定し、画面に指示することができる。特に、人の
体内を流れる血液と同等の変質していない生の血
液細胞について症状の判定指示を行なうものであ
るために、従来方法に比較すると症状の内容をよ
り適格に把握し、適正な判定を行うことができ、
患者の病気快復や健康を良好に維持する大きな手
助けとなる。これらの検出判定の操作は迅速かつ
正確に行なわれるので、その診断時間を大きく短
縮することができる。これにより、緊急時の判定
にも利用することができ、また、気軽に診断を受
けることができる。 In this way, the method for instructing automatic blood analysis and judgment of the present invention can be performed by simply enlarging a small amount of unaltered raw blood collected from a patient using a microscope, and visually observing the blood cell image on the screen. It can be used for diagnosis by doctors and explanations for patients. In addition, even after that, the symptoms and active ingredients corresponding to the blood cell image can be automatically detected, determined, and instructed on the screen. In particular, since the system instructs the judgment of symptoms using unaltered living blood cells, which are equivalent to the blood flowing in the human body, compared to conventional methods, it is possible to understand the content of symptoms more accurately and make appropriate judgments. can be done,
It is a great help for patients to recover from illness and maintain good health. Since these detection/judgment operations are performed quickly and accurately, the diagnostic time can be greatly shortened. Thereby, it can be used for judgment in an emergency, and it is also possible to receive a diagnosis easily.
第1図から第21図は各種血液細胞の1000倍の
顕微鏡写真、第22図は本発明の血液の自動分析
判定指示方法に用いる装置の一実施例を示す系統
図である。
1……顕微鏡、2……テレビカメラ、3……デ
イスプレー機、4……データ採取器、4a……デ
ータ信号、7……演算器、7a……指示信号。
FIGS. 1 to 21 are micrographs of various blood cells magnified 1000 times, and FIG. 22 is a system diagram showing an embodiment of the apparatus used in the automatic blood analysis and judgment instruction method of the present invention. 1... Microscope, 2... Television camera, 3... Display device, 4... Data collector, 4a... Data signal, 7... Arithmetic unit, 7a... Instruction signal.
Claims (1)
より拡大し、この顕微鏡によつて拡大された変質
前の血液細胞像をテレビカメラにより撮像し、こ
のテレビカメラから送られて来る信号を受けて前
記血液細胞像をデイスプレー機に映し出させ、デ
ータ採取器により前記血液細胞像から各種血液細
胞の状態を検出するとともにその状態に応じたデ
ータ信号を発生させ、演算器によりこのデータ信
号を予め記憶してある各種血液細胞像状態と比較
し、そのデータ信号に相当する症状と有効投与成
分とを選択して前記デイスプレー機に表示させる
指示信号を発することにより血液の分析判定内容
をデイスプレー機に表示させることを特徴とする
血液の自動分析判定指示方法。1. The sampled blood cells are magnified with a microscope before being altered, the image of the blood cells before the alteration enlarged by the microscope is imaged with a television camera, and the above-mentioned blood cells are A blood cell image is projected on a display device, a data collector detects the state of various blood cells from the blood cell image, and a data signal corresponding to the state is generated, and this data signal is stored in advance by an arithmetic unit. The contents of the blood analysis and judgment are displayed on the display machine by comparing the status of various blood cell images and emitting an instruction signal to select the symptoms and effective administration ingredients corresponding to the data signals and displaying them on the display machine. A method for instructing automatic blood analysis and determination, characterized by displaying the information.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59013928A JPS60158352A (en) | 1984-01-28 | 1984-01-28 | Automatic blood analyzing, judging and displaying apparatus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59013928A JPS60158352A (en) | 1984-01-28 | 1984-01-28 | Automatic blood analyzing, judging and displaying apparatus |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60158352A JPS60158352A (en) | 1985-08-19 |
JPH0531107B2 true JPH0531107B2 (en) | 1993-05-11 |
Family
ID=11846839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59013928A Granted JPS60158352A (en) | 1984-01-28 | 1984-01-28 | Automatic blood analyzing, judging and displaying apparatus |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60158352A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61258167A (en) * | 1985-05-10 | 1986-11-15 | Hitachi Ltd | Automatic blood cell classifying device |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54119294A (en) * | 1978-02-03 | 1979-09-17 | Rush Presbyterian St Luke | Method and device for automatically analyzing erythrocyte in sample |
JPS56133659A (en) * | 1980-03-25 | 1981-10-19 | Omron Tateisi Electronics Co | Cell analyzer |
JPS57103059A (en) * | 1980-12-18 | 1982-06-26 | Omron Tateisi Electronics Co | Apparatus for analysis of cell |
JPS57153367A (en) * | 1981-03-18 | 1982-09-21 | Toshiba Corp | Diagnostic device of cell |
JPS58223868A (en) * | 1982-06-22 | 1983-12-26 | Toshiba Corp | Automatic cell diagnosing device |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49134552A (en) * | 1973-04-28 | 1974-12-25 | ||
US3948678A (en) * | 1974-01-07 | 1976-04-06 | John Dezzani | Solder iron dressing system having a teflon packing |
JPS5364646A (en) * | 1977-06-23 | 1978-06-09 | Tasuku Okazaki | Cleaning agent of solder iron tip |
JPS58199658A (en) * | 1982-05-18 | 1983-11-21 | Asahi Kagaku Kenkyusho:Kk | Method and apparatus for cleaning soldering iron |
-
1984
- 1984-01-28 JP JP59013928A patent/JPS60158352A/en active Granted
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54119294A (en) * | 1978-02-03 | 1979-09-17 | Rush Presbyterian St Luke | Method and device for automatically analyzing erythrocyte in sample |
JPS56133659A (en) * | 1980-03-25 | 1981-10-19 | Omron Tateisi Electronics Co | Cell analyzer |
JPS57103059A (en) * | 1980-12-18 | 1982-06-26 | Omron Tateisi Electronics Co | Apparatus for analysis of cell |
JPS57153367A (en) * | 1981-03-18 | 1982-09-21 | Toshiba Corp | Diagnostic device of cell |
JPS58223868A (en) * | 1982-06-22 | 1983-12-26 | Toshiba Corp | Automatic cell diagnosing device |
Also Published As
Publication number | Publication date |
---|---|
JPS60158352A (en) | 1985-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aharon-Peretz et al. | Vascular dementia and dementia of the Alzheimer type: cognition, ventricular size, and leuko-araiosis | |
De Bats et al. | Age-related macular degeneration screening using a nonmydriatic digital color fundus camera and telemedicine | |
Caplan | Stroke | |
Hawk et al. | Affective modulation of tactile startle | |
Mesulam | Dementia: Its definition, differential diagnosis, and subtypes | |
CN108541859A (en) | A kind of DHA algal oil solid beverage | |
Numanović et al. | Presence and resistance of Streptococcus agalactiae in vaginal specimens of pregnant and adult non-pregnant women and association with other aerobic bacteria | |
Perlman | Dysphagia in stroke patients | |
JPH0531107B2 (en) | ||
CN116153508A (en) | Health intervention system based on active health index | |
Wood et al. | Adaptive and maladaptive utilization of color cues by patients with mild to moderate Alzheimer's disease | |
Izquierdo et al. | Neuroradiologic abnormalities in Marchiafava-Bignami disease of benign evolution | |
US20200289588A1 (en) | Bifidobacterium longum ncimb 41676 | |
Retzloff et al. | Optic neuritis with transient total blindness during lactation | |
Duncan et al. | The night vision threshold test (NVTT): a simple instrument for testing dark adaptation in young children | |
Sullivan et al. | Lateral deviation of the eyes on forced lid closure in patients with cerebral lesions | |
Al Meslet et al. | Knowledge and awareness of sickle cell anemia among dental students in Riyadh Elm University | |
US20230414681A1 (en) | Bifidobacterium longum ncimb 41676 | |
Galderisi et al. | Quantitative EEG test dose procedure in the prediction of response to treatment with antipsychotic drugs | |
Kaykisiz et al. | The diagnosis of pulmonary embolism without contrastis not always Challenging: be aware of hyperdense lumen sign | |
Nri-Ezedi et al. | Bloodless management of significantly elevated transcranial Doppler velocity value in a Jehovah's witness child with sickle cell disease: A tertiary centre experience-A case report | |
Ashawari et al. | Scholars Journal of Dental Sciences | |
Papantoniou et al. | Peduncular hallucinosis associated with pontine hemorrhage in an adult patient | |
JP2023159833A (en) | Brain function improving composition | |
Limber | Genetic Blood and Bleeding Disorders |